Invasive Meningococcal Disease

1
Pipeline Programs
2
Companies
50
Clinical Trials
5 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Novartis
NovartisBASEL, Switzerland
1 program
1
MeningococcalPhase 21 trial
Active Trials
NCT01272180Completed484Est. Sep 2012
Pfizer
PfizerNEW YORK, NY
1 program
surveillanceN/A5 trials
Active Trials
NCT04982848Not Yet Recruiting600Est. Nov 2028
NCT06581848Active Not Recruiting150Est. Jan 2030
NCT04889495Withdrawn0Est. Aug 2025
+2 more trials

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
2027
2028
2029
2030
NovartisMeningococcal
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance
Pfizersurveillance

Showing 15 of 50 trials with date data

Clinical Trials (50)

Total enrollment: 109,850 patients across 50 trials

NCT01272180NovartisMeningococcal

Safety and Immunogenicity of Different Meningitis Vaccine Formulations in Adolescents and Young Adults

Start: Aug 2011Est. completion: Sep 2012484 patients
Phase 2Completed
NCT04982848Pfizersurveillance

Korea Post Marketing Surveillance (PMS) Study of Talzenna®

Start: Jun 2027Est. completion: Nov 2028600 patients
N/ANot Yet Recruiting
NCT06581848Pfizersurveillance

Korean Post Marketing Surveillance for ELREXFIO (Elranatamab).

Start: Jun 2025Est. completion: Jan 2030150 patients
N/AActive Not Recruiting
NCT04889495Pfizersurveillance

A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in Domestic Patients With Various Cancer

Start: May 2025Est. completion: Aug 20250
N/AWithdrawn
NCT06743334Pfizersurveillance

Secondary Databased Post-marketing Surveillance Study of BNT162b2

Start: Apr 2025Est. completion: May 20251 patients
N/ACompleted
NCT05754710Pfizersurveillance

Korea Xeljanz Post-marketing Surveillance for Juvenile Idiopathic Arthritis

Start: Apr 2024Est. completion: Sep 202610 patients
N/ARecruiting
NCT05599412Pfizersurveillance

Post Marketing Surveillance(PMS) Study of Lorviqua in Korea

Start: May 2023Est. completion: Mar 2028600 patients
N/ARecruiting
NCT05131100Pfizersurveillance

Korean Regulatory Post Marketing Surveillance for Somavert

Start: Jul 2022Est. completion: Sep 2026100 patients
N/ARecruiting
NCT05032976Pfizersurveillance

Korea Comirnaty Post-marketing Surveillance

Start: Mar 2022Est. completion: Apr 202612,000 patients
N/AActive Not Recruiting
NCT04744454Pfizersurveillance

Post Marketing Surveillance (PMS) Study of Cresemba in Korea.

Start: Oct 2021Est. completion: Jan 2026600 patients
N/ARecruiting
NCT04801329Pfizersurveillance

Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy

Start: Jun 2021Est. completion: Dec 2026110 patients
N/AActive Not Recruiting
NCT04748445Pfizersurveillance

Acute Respiratory Illness Surveillance (AcRIS) With Mobile Application in a Low-Interventional Decentralized Study.

Start: Apr 2021Est. completion: Apr 20229,151 patients
N/ACompleted
NCT04447521Pfizersurveillance

Surveillance of Non-invasive Streptococcus Pneumoniae Infections in Belgium

Start: Sep 2020Est. completion: Dec 20253,600 patients
N/AUnknown
NCT04307134Pfizersurveillance

Besponsa Post Marketing Surveillance Study

Start: Jul 2020Est. completion: Dec 2024108 patients
N/ACompleted
NCT04071405Pfizersurveillance

Korea Post-marketing Surveillance for Xeljanz (Registered) in Ulcerative Colitis Patients

Start: May 2020Est. completion: Sep 2022110 patients
N/ACompleted
NCT02156895Pfizersurveillance

Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea

Start: Jul 2018Est. completion: Aug 2021111 patients
N/ACompleted
NCT03445637Pfizersurveillance

Post Marketing Surveillance Study to Observe Safety and Efficacy of IBRANCE®

Start: Feb 2018Est. completion: Jul 2025552 patients
N/ACompleted
NCT03034044Pfizersurveillance

Post-Marketing Surveillance To Observe Safety And Efficacy Of Xyntha Solofuse Prefilled Syringe

Start: Jan 2017Est. completion: Jan 2018106 patients
N/ACompleted
NCT02984020Pfizersurveillance

Korean Post-marketing Surveillance for Xeljanz

Start: May 2016Est. completion: Jun 20221,041 patients
N/ACompleted
NCT02548949Pfizersurveillance

Korean Post Marketing Surveillance to Observe Effectiveness and Safety of PRISTIQ

Start: Apr 2016Est. completion: Feb 2020700 patients
N/ACompleted
NCT02792504Pfizersurveillance

Post Marketing Surveillance To Observe Safety And Efficacy Of Duavive

Start: Mar 2016Est. completion: Jul 2020669 patients
N/ACompleted
NCT04184336Pfizersurveillance

Enhanced Population-based Core Surveillance of Meningococcal Invasive Infections at Participating Centers Across Canada

Start: Jan 2016Est. completion: Dec 2022400 patients
N/AUnknown
NCT02533258Pfizersurveillance

Post-Marketing Surveillance Study To Observe INLYTA® Treatment Dosing Pattern, Safety And Effectiveness In Taiwan Real World Routine Practice

Start: Dec 2015Est. completion: May 201613 patients
N/ACompleted
NCT01834222Pfizersurveillance

Post Market Surveillance to Observe Safety of Prevenar13™ in Adults

Start: Dec 2013Est. completion: Mar 2016659 patients
N/ACompleted
NCT01793142Pfizersurveillance

Post Marketing Surveillance For General Drug Use To Assess the Safety And Efficacy Profile Of Viviant In Usual Practice

Start: Oct 2013Est. completion: May 20173,430 patients
N/ACompleted
NCT02007655Pfizersurveillance

Eliquis Safety Surveillance in Japanese Patients With NonValvular Atrial Fibrillation

Start: Sep 2013Est. completion: Aug 20166,372 patients
N/ACompleted
NCT01781442Pfizersurveillance

A Post Marketing Surveillance As Required By Philippine Food And Drug Administration

Start: Jun 2013Est. completion: Jun 20150
N/AWithdrawn
NCT01793688Pfizersurveillance

Special Use-Result Surveillance of Unasyn-S (Kit) for Intravenous Use - A Surveillance on High-dose (>6 g Daily) Administration -

Start: Mar 2013Est. completion: Jan 2016982 patients
N/ACompleted
NCT01432249Pfizersurveillance

Post Marketing Surveillance To Observe Safety And Efficacy Of Enbrel In Pediatric Patients With Psoriasis

Start: Mar 2013Est. completion: Sep 20130
N/AWithdrawn
NCT00802854Pfizersurveillance

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Eraxis® IV

Start: Mar 2012Est. completion: May 2016244 patients
N/ACompleted
NCT01396434Pfizersurveillance

Safety Surveillance of Pneumococcal 13-valent Conjugate Vaccine Among Filipinos

Start: Dec 2011Est. completion: May 20143,006 patients
N/ACompleted
NCT02140853Pfizersurveillance

MDR Bacilli Surveillance and Clinical Feature in China

Start: Nov 2011Est. completion: Dec 20151,500 patients
N/AUnknown
NCT01509105Pfizersurveillance

Prevenar13 Post Market Surveillance

Start: Sep 2011Est. completion: Jan 2016649 patients
N/ACompleted
NCT01260311Pfizersurveillance

Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder

Start: Feb 2011Est. completion: Oct 2013508 patients
N/ACompleted
NCT01521897Pfizersurveillance

Prevenar Special Use-result Surveillance in Japan (Regulatory PostMarketing Commitment Plan)

Start: Sep 2010Est. completion: Apr 20151,143 patients
N/ACompleted
NCT01047358Pfizersurveillance

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Aromasin In The Patients With Early Or Advanced Breast Cancer

Start: Jun 2010Est. completion: Jun 2014206 patients
N/ACompleted
NCT01003886Pfizersurveillance

A Post Marketing Surveillance Study Of Doxazosin Mesylate GITS Among Filipino Patients With Benign Prostatic Hyperplasia (BPH)

Start: May 2009Est. completion: Jan 2011989 patients
N/ACompleted
NCT00794365Pfizersurveillance

Post Marketing Surveillance Study of Champix in Smoking Cessation for Filipino Patients

Start: Jul 2008Est. completion: Nov 2009330 patients
N/ACompleted
NCT00672841Pfizersurveillance

β-D-Glucan (BDG) Surveillance With Preemptive Anidulafungin vs. Standard Care for Invasive Candidiasis in Surgical Intensive Care Unit (SICU) Patients

Start: Jun 2008Est. completion: Jan 201164 patients
N/ACompleted
NCT00484185Pfizersurveillance

Post Marketing Surveillance To Observe Safety and Efficacy Of BeneFIX In Patients With Hemophilia B

Start: Aug 2007Est. completion: Jun 2012183 patients
N/ACompleted
NCT00796159Pfizersurveillance

Post-Marketing Surveillance Of Olmesartan Medoxomil In Combination With Hydrochlorothiazide

Start: Jul 2007Est. completion: Dec 20081,723 patients
N/ACompleted
NCT00483002Pfizersurveillance

Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets

Start: Jun 2007Est. completion: May 20113,719 patients
N/ACompleted
NCT00428051Pfizersurveillance

Colombia Epidemiologic Surveillance Study

Start: Sep 2006Est. completion: Oct 201132,867 patients
N/ATerminated
NCT00892008Pfizersurveillance

A Post Marketing Surveillance Study On Pregabalin (Lyrica) On Efficacy, Safety And Tolerability Of Pregabalin

Start: Sep 2006Est. completion: Aug 20082,278 patients
N/ACompleted
NCT00488397Pfizersurveillance

Tigecycline In-Vitro Surveillance Study In Taiwan

Start: Aug 2006Est. completion: Feb 20117,902 patients
N/ACompleted
NCT01220180Pfizersurveillance

Lyrica (Pregabalin) Korean Post Marketing Surveillance Study

Start: Jul 2006Est. completion: Apr 20114,175 patients
N/ACompleted
NCT00901602Pfizersurveillance

Lebanese Interhospital Pneumococcal Surveillance Program

Start: Oct 2005Est. completion: Oct 2030700 patients
N/ARecruiting
NCT01053429Pfizersurveillance

A Non-Interventional Post-Marketing Surveillance Study to Evaluate the Safety and Efficacy of Zeldox Capsule

Start: Jun 2005Est. completion: Feb 20103,391 patients
N/ACompleted
NCT00195390Pfizersurveillance

Study Investigating Administration of Prevenar for Post-Marketing Surveillance

Start: Jul 2004Est. completion: Jul 2008600 patients
N/ACompleted
NCT00195403Pfizersurveillance

A Drug Use Investigation of ENBREL for Post-marketing Surveillance (PMS) for RA and PsA

Start: May 2004Est. completion: Feb 20081,014 patients
N/ACompleted

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

5 actively recruiting trials targeting 109,850 patients
2 companies competing in this space